Trial · NCT04517747
Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction
NCT04517747, Not applicable, Completed, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction. Trials, record NCT04517747. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04517747
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction
- NCT number
- NCT04517747
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Conditions
- Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction
- Interventions
- Ramucirumab, TAS 102
- First posted
- 2020-08-18
- Last updated
- 2023-02-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tolerability and toxicity: rate of serious adverse events (SAEs) of any cause | Frist Treatment until 30 days after end of treatment, up to 5 months | The primary endpoint of the study is tolerability and toxicity, defined by the rate of serious adverse events (SAEs) of any cause according to CTCAE v5.0 |
| Secondary | Rate of treatment-related AEs and SAE | Frist Treatment until 30 days after end of treatment, up to 5 months | Rate of treatment-related AEs and SAEs according to CTCAE v5.0 |
| Secondary | Adverse events for neutropenia | Frist Treatment until 30 days after end of treatment, up to 5 months | Rate of grade 3 or worse adverse events for neutropenia |
| Secondary | Adverse events for anemia | Frist Treatment until 30 days after end of treatment, up to 5 months | Rate of grade 3 or worse adverse events for anemia |
| Secondary | Adverse events for leucopenia | Frist Treatment until 30 days after end of treatment, up to 5 months | Rate of grade 3 or worse adverse events for leucopenia |
| Secondary | Adverse events for thrombocytopenia | Frist Treatment until 30 days after end of treatment, up to 5 months | Rate of grade 3 or worse adverse events for thrombocytopenia |
| Secondary | Abnormal laboratory parameters | Frist Treatment until 30 days after end of treatment, up to 5 months | Frequency of abnormal laboratory parameters |
| Secondary | Progression Free Survival (PFS) | Progression free survival (PFS) is defined as the time from enrollment to the first documented evidence of disease progression or death; up to 16 months. | Progression Free Survival (PFS) according to RECIST 1.1, Progression free survival (PFS) is defined as the time from enrollment to the first documented evidence of disease progression or death. If no information will be available for the evaluation of progression, patients will be censored at the timepoint of last tumor assessment. |
| Secondary | Objective Response Rate (ORR) | defined as the time from enrollment up to 16 months. | Objective response rate is defined as proportion of patients with a best overall response of complete response (CR) or partial response (PR). Tumor response will be evaluated using RECIST 1.1 criteria. |
| Secondary | Overall survival | Overall survival (OS) is defined as the time from enrollment to the date of death from any cause.; up to 16 months. | Overall survival |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37455496 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04517747
GET https://conductscience.org/api/trials/v1/NCT04517747/registered